Cannabis Rescheduling to Schedule III: What It Means for Cannabis Businesses

The U.S. Department of Justice has begun the long-anticipated shift of cannabis from Schedule I to Schedule III under the Controlled Substances Act. The action follows a presidential directive issued late last year and marks a notable change in how federal regulators approach cannabis, particularly in the context of medical use, research, and taxation. The move signals progress, yet stops short of federal legalization, leaving key aspects of the industry subject to existing restrictions.

For business leaders, the development introduces a more nuanced regulatory environment rather than a clean transition. Certain state-licensed medical cannabis operations may see immediate changes in federal tax treatment and compliance expectations, while recreational activities remain outside the scope of relief. The phased rollout, combined with ongoing administrative review, creates a landscape where benefits may accrue unevenly across business models, requiring careful evaluation and planning.

Tax Treatment and Regulatory Scope

The most immediate consequence of reclassification centers on federal tax treatment. State-licensed medical cannabis businesses are expected to move out of the constraints of Internal Revenue Code Section 280E, which has historically disallowed standard business deductions for companies trafficking in Schedule I substances. This change may allow eligible operators to deduct ordinary and necessary expenses, potentially improving cash flow, margins, and financial reporting outcomes. The Department of Justice has also signaled support for retroactive relief, though the scope and mechanics of such treatment remain subject to further guidance and coordination with the Treasury.

The benefit, however, is not uniform. Companies operating both medical and recreational lines may face the practical challenge of segmenting revenue, costs, and activities to determine which portions of the business qualify for relief. Until broader rescheduling is finalized, non-medical cannabis remains a Schedule I substance at the federal level, preserving existing tax limitations and compliance exposure for those operations.

Beyond taxation, the rule introduces a more layered compliance framework. State-licensed entities seeking alignment with Schedule III requirements will need to engage with federal registration processes administered by the Drug Enforcement Administration, even as they continue to operate within established state systems.

Operational Complexity Rises as Opportunities Expand

Beyond tax treatment, the reclassification begins to reshape how cannabis businesses operate within a federally recognized framework. The Department of Justice has outlined an expedited pathway for state-licensed medical operators to obtain federal registration, introducing a dual-layer system that blends state oversight with federal controls. While this approach may reduce disruption for established medical programs, it also adds new compliance considerations, including registration requirements, facility access provisions, and enhanced recordkeeping standards.

The rule also opens the door to expanded research activity. For the first time, federally registered researchers may obtain cannabis products directly from state-licensed entities without facing enforcement risk under the Controlled Substances Act. This change may accelerate clinical research and support the development of FDA-approved therapies, gradually strengthening the scientific and regulatory foundation of the market.

At the same time, key limitations remain in place. Recreational cannabis continues to fall outside the scope of federal relief, and broader rescheduling is subject to an expedited administrative hearing process that may shape the final framework. Questions tied to timing, implementation, and enforcement posture remain open, particularly for businesses operating across multiple state markets or serving both medical and recreational segments.

Organizations operating in this space may benefit from a measured approach, balancing near-term opportunities with ongoing regulatory uncertainty. AAFCPAs will continue to monitor developments, including guidance from the IRS and the Treasury Department.

How We Help

AAFCPAs works with cannabis businesses nationwide to navigate shifting federal and state requirements, with a focus on aligning tax strategy, financial reporting, and operational decision-making as regulations evolve. In light of the move toward Schedule III, organizations may face new considerations tied to Section 280E relief, entity structuring, and the segmentation of medical and recreational activities, along with added federal compliance layers. AAFCPAs’ multi-disciplinary team brings more than a decade of experience advising operators, investors, and multistate businesses in the cannabis industry, offering integrated tax, accounting, advisory, and transaction support designed to strengthen cash flow, manage risk, and support long-term growth. The firm remains actively engaged in monitoring policy developments and contributing to industry dialogue, helping clients anticipate change and respond with informed, practical strategies as the regulatory landscape continues to develop.

These insights were contributed by David McManus, CPA, CGMA, Tax Partner & National Cannabis Practice Leader and David Gravel, CPA, MPAc, Tax Director.

Questions? Reach out to our authors directly or your AAFCPAs partner.

AAFCPAs offers a wealth of resources on cannabis business strategy. Subscribe to get alerts and insights in your inbox.